傳染病治療藥的研發課題及市場 是由出版商Insight Pharma Reports在2006年09月所出版的。
這份英文市場調查報告書包含200 pages 價格從美金2750起跳。
2005年全球的傳染病治療藥的銷售成績達到445億美元,在今後5年內這個數字預計將成長為2倍。
因遺傳基因領域的調查獲得全球高度評價的美國市調公司 Insight Pharma Reports (總公司:麻薩諸塞州),針對傳染病治療藥的研發課題及市場進行詳細的調查分析,並出版調查報告書 "Infectious Diseases: R&D Challenges and Market Drivers" 。
本報告書內容包括:全球流行病的爆發、生物恐怖襲擊的威脅、分子生物科技及奈米科技的發展、慢性病與傳染病的關係等調查分析結果,以及主要企業的資料。內容綱要摘記如下:
第1章 新的微生物需求及帶動傳染病治療藥市場發展的主要因素
- 傳染病之發現・再度發現・擴散
- 嚴重的抗藥性問題
- 生物防禦
- 技術成長與知識的累積
- 食品安全相關顧慮
- 動物的健康
- 慢性病的病因學
第2章 治療的課題:作為移動目標的微生物
- 介紹
- HIV/AIDS 抗逆轉錄病毒藥
- 新的抗生素
- 禽流感
- 逆轉濾過性病毒
- 疫苗產業的課題
第3章 檢查工作:傳染病之診斷
- 介紹
- 分子診斷
- 血液安全性
- 2003年至2006年禽流感的流行:迅速診斷檢查的重要性
第4章 商機:利基市場的存在
- 介紹
- 專利到期與價格下降
- 抗菌劑的抗藥性與市場機會
- 生物防禦
- 傳染病之現在與未來
- 掌握利基市場
- 被忽略疾病(Neglected Disease)治療藥的研發
- 合作與整合
- 最主要的課題
第5章 企業資料
- Acambis
- Adlyfe Inc.
- Akonni Biosystems
- Alnylam Pharmaceuticals
- Arbor Vita Corporation
- Biophage Pharma Inc.
- CEL-SCI Corporation
- CombiMatrix Corporation
- Cubist Pharmaceuticals, Inc.
- Gilead Sciences, Inc.
- NanoBio Corporation
- Nanosphere, Inc.
- Obetech, LLC
- Panacos Pharmaceuticals, Inc.
- PowderMed Limited
- Progenics Pharmaceuticals, Inc.
- Ribomed Biotechnologies, Inc.
- Tanox, Inc.
- Targanta Therapeutics, Inc.
- Tm Bioscience Corporation
附錄
Abstract
Global sales of anti-infective drugs reached $44.5 billion in 2005 and will
likely double over the next 5 years. Antibiotics led the category at $31
billion. Infectious Diseases: R&D Challenges and Market Drivers, a new
CHA Advances report, analyzes the factors driving infectious disease
therapeutic and diagnostic markets, the key business and technology trends,
targets and drugs in development, companies at the forefront of anti-infective
R&D, and the commercial opportunities and challenges of anti-infective drugs
and vaccines.
Past hurdles to pursuing anti-infective drug development\including
historically low margins, short therapeutic regimens, manufacturing
challenges, and regulatory problems associated with developing drugs for
"unvalidated" microbial targets\are no longer discouraging entrants. Big
Pharma has rediscovered the anti-infectives market and is bolstering its
pipelines through licensing agreements and acquisitions. And smaller, less
risk-aversive biopharmaceutical companies have discovered the allure of
substantial profits while also meeting public health goals. A quantitative
survey (commissioned by CHA in July/August 2006, N=83) of individuals involved
in infectious disease R&D and business development sheds light on the research
priorities and R&D trends in industry, government, and academia.
The evolution of drug resistance is the most powerful driver of anti-infective
R&D. Other factors fueling research that are assessed in the report include:
- The emergence of pandemics
- Perceived and actual threat of bioterrorism
- Advances in molecular biology and nanotechnology
- Accumulating evidence that many chronic diseases have an infectious
etiology
Infectious Diseases: R&D Challenges and Market Drivers drills down into
the emerging commercial opportunities, providing expert insight into:
- Recent developments and opportunities in the infectious disease testing
market, which accounts for 80% of the estimated $6.5 billion global molecular
diagnostics market
- The vaccines market, which has shed its low-margin image and posted
10-fold growth over the past decade driven by new threats, new technologies,
and new targets
- Food safety and the food microbiology testing market
- The expanding market for veterinary drugs and diagnostics
- Niche opportunities in antimicrobial resistance
- Opportunities-and a practical guide to capitalizing on them-in Biodefense
- Neglected disease markets both large and small, including Malaria, TB,
Onchocerciasis, Dengue, and more.
Individuals in R&D, business development, strategic planning, and marketing
will benefit from the hundreds of hours of primary and secondary research that
went into Infectious Diseases: R&D Challenges and Market Drivers.
About the Author
Leslie A. Pray, PhD, is a science writer and consultant to the Forum on
Microbial Threats at the National Academy of Sciences. She has written
extensively on a range of genetic, biotechnology, infectious disease, public
health policy, and higher education issues for The Scientist, Genomics and
Proteomics, The Chronicle of Higher Education, Orion, the American Chemical
Society, the American Association for the Advancement of Science, Oak Ridge
National Laboratory, and the CBR Institute for Biomedical Research, among
others. Dr. Pray received her PhD in population genetics from the University
of Vermont and her BA degree from the University of California , Berkeley. An
elected member of Sigma Xi, she has been the recipient of numerous scientific
research awards, including an American Society of Naturalists Young
Investigator Award and a National Science Foundation Environmental Biology
Postdoctoral Fellowship. Dr. Pray can be reached at lpray@nasw.org .
Table of Contents
CHAPTER 1
NEW MICROBIAL DEMANDS AND MAJOR DRIVERS OF THE ANTI-INFECTIVE MARKETPLACE
- 1.1. The Emergence, Re-emergence, and Spread of Infectious Diseases
- 1.2. The Very Serious Problem of Drug Resistance
- 1.3. Biodefense
- 1.4. Technological Growth and Increased Knowledge
- 1.5. Growing Concerns about Food Safety
- 1.6. Animal Health
- 1.7. The Infectious Etiology of Chronic Diseases
CHAPTER 2
THERAPEUTIC CHALLENGES: MICROBES AS MOVING TARGETS
- 2.1. Introduction
- 2.2. HIV/AIDS Antiretrovirals: Growth in a Mature Market
- 2.3. Adding to the Antibiotic Arsenal
- Phage Therapy: A New Market Niche for Alternative Antibacterials?
- 2.4. Bird Flu
- The Current Avian Influenza A (H5N1) Outbreak
- Influenza Therapeutics
- Oseltamivir (Tamiflu)
- 2.5. Retroviruses: A Global Threat More Serious Than Influenza?
- 2.6. Vaccine Industry Challenges
- Infectious Agent Vaccines for the Prevention of Chronic Disease
- Human Papilloma Virus Vaccines
- Changing Trends in Vaccine Technology and Targets
- New Vaccine Targets
- The Race To Make a Universal Influenza Vaccine
- M2 Vaccines
- NP Vaccines
- When Will Plant-Based Vaccines Be Ripe for Marketing?
CHAPTER 3
DOING THE DETECTIVE WORK: INFECTIOUS DISEASE DIAGNOSTICS
- 3.1. Introduction
- 3.2. Molecular Diagnostics
- Advantages of Molecular Versus Culture-Based Detection
- Human Papilloma Virus Testing: The Fastest-Growing Molecular Diagnostic
Test
- HIV and HCV Viral Load Tests
- HCV Testing
- 3.3. Blood Safety: The Emerging Problem of Bacterial Contamination
- Other Blood-Borne Pathogens of Concern
- The Emerging Problem of Transfusion-Associated Bacterial Contamination
- 3.4. The 2003 to 2006 Avian Influenza Outbreak: The Importance of Rapid
Diagnostic Testing
- Prompt Treatment
- Surveillance and WHO Notification
- Preventing Dissemination and Opportunities for Viral Evolution
- The Ideal Influenza Test
- Available Avian Influenza Diagnostic Tests
- PCR-Based Nucleic Acid Amplification Tests
- Commercial Availability of "Rapid" Tests Still Requiring Validation
CHAPTER 4
COMMERCIAL OPPORTUNITIES: COMFORTABLE NICHES EXIST FOR BOTH BIG PHARMA AND SMALL BIOTECHS
- 4.1. Introduction
- 4.2. Patent Expiration and Price Drops
- 4.3. Antimicrobial Resistance and Market Opportunities
- Products and Profitability: Major and Small-Company Players
- 4.4. Biodefense: A Call to Industry
- Opportunities and Challenges for Small Companies Seeking Government
Biodefense Contracts
- Companies on Government Contract
- Finding the Funds
- Efforts to Strengthen BioShield: Looking to Large Pharma
- 4.5. The Present and Future Burden of Infectious Disease
- 4.6. Finding Your Market Niche
- 4.7. Neglected Infectious Disease Drug Development: Opportunities for All,
Big and Small
- Major Neglected Infectious Diseases
- Malaria
- Tuberculosis
- Onchocerciasis
- Dengue
- Visceral Leishmaniasis
- Lymphatic Filariasis
- 4.8. Collaboration and Consolidation
- 4.9. The Biggest Challenge Is Basic Science: The Red Queen Race
CHAPTER 5
COMPANY PROFILES
- 5.1. Acambis
- 5.2. Adlyfe Inc.
- 5.3. Akonni Biosystems
- 5.4. Alnylam Pharmaceuticals
- 5.5. Arbor Vita Corporation
- 5.6. Biophage Pharma Inc.
- 5.7. CEL-SCI Corporation
- 5.8. CombiMatrix Corporation
- 5.9. Cubist Pharmaceuticals, Inc.
- 5.10. Gilead Sciences, Inc.
- 5.11. NanoBio Corporation
- 5.12. Nanosphere, Inc.
- 5.13. Obetech, LLC
- 5.14. Panacos Pharmaceuticals, Inc.
- 5.15. PowderMed Limited
- 5.16. Progenics Pharmaceuticals, Inc.
- 5.17. Ribomed Biotechnologies, Inc.
- 5.18. Tanox, Inc.
- 5.19. Targanta Therapeutics, Inc.
- 5.20. Tm Bioscience Corporation
APPENDIX
CHA ADVANCES INFECTIOUS DISEASE SURVEY - July/August 2006 (n = 83)
References
Glossary
Company Index with Web Sites
|